| 1 | cut-off | 1,599 |
| 2 | top | 1,555 |
| 3 | cutoff | 1,505 |
| 4 | nadir | 468 |
| 5 | willingness-to-pay | 146 |
| 6 | isoelectric | 138 |
| 7 | fermi | 113 |
| 8 | inflection | 81 |
| 9 | cutpoint | 50 |
| 10 | hlb | 26 |
| 11 | break-even | 20 |
| 12 | he-sea | 18 |
| 13 | icru | 18 |
| 14 | supercooling | 15 |
| 15 | dew | 12 |
| 16 | rcof | 12 |
| 17 | comlex-usa | 11 |
| 18 | ezscan | 11 |
| 19 | no-observed-adverse-effect | 11 |
| 20 | b3lyp/6-31g* | 10 |
| 21 | cho/naa | 10 |
| 22 | pmadl-8 | 9 |
| 23 | t1rho | 9 |
| 24 | hrr₆₀ | 8 |
| 25 | pre-activation | 8 |
| 26 | tonset | 8 |
| 27 | caliche | 7 |
| 28 | d-10 | 7 |
| 29 | fsvr | 7 |
| 30 | high-current | 7 |
| 31 | insulative | 7 |
| 32 | knuckle | 7 |
| 33 | maxwellian | 7 |
| 34 | nonwear | 7 |
| 35 | 'threshold | 6 |
| 36 | pre-program | 6 |
| 37 | who-teq | 6 |
| 38 | aucplasma | 5 |
| 39 | carborhodation | 5 |
| 40 | high-hb | 5 |
| 41 | time-integral | 5 |
| 42 | tricritical | 5 |
| 43 | 9th-grade | 4 |
| 44 | aunp/gce | 4 |
| 45 | neck-occiput | 4 |
| 46 | phbhhx-l | 4 |
| 47 | romhilt-estes | 4 |
| 48 | tvlat | 4 |
| 49 | age-distribution | 3 |
| 50 | cbfb-myh11 | 3 |
| 51 | cis-interaction | 3 |
| 52 | curcumin-based | 3 |
| 53 | horrat | 3 |
| 54 | kid21 | 3 |
| 55 | lt₅₀ | 3 |
| 56 | nfw | 3 |
| 57 | nonmeridian | 3 |
| 58 | twilight | 3 |
| 59 | wuxin | 3 |
| 60 | ar-model | 2 |
| 61 | blood-oxygen | 2 |
| 62 | constant-murley-score | 2 |
| 63 | creatinine-clearance | 2 |
| 64 | cut-of | 2 |
| 65 | d58 | 2 |
| 66 | desmoglein-2 | 2 |
| 67 | dft-computed | 2 |
| 68 | druid | 2 |
| 69 | elisa-igg | 2 |
| 70 | empiriocriticist | 2 |
| 71 | ep-determined | 2 |
| 72 | etsev | 2 |
| 73 | high-tli | 2 |
| 74 | historical-control | 2 |
| 75 | ldl-lipoprotein | 2 |
| 76 | low-hb | 2 |
| 77 | lǜ | 2 |
| 78 | machine-milled | 2 |
| 79 | millipede | 2 |
| 80 | oracfl | 2 |
| 81 | osteo-induction | 2 |
| 82 | percent-weight-loss | 2 |
| 83 | pre-fasting | 2 |
| 84 | proof-of-efficacy | 2 |
| 85 | reculture | 2 |
| 86 | repeat-induced | 2 |
| 87 | respiratory-compensation | 2 |
| 88 | rothera | 2 |
| 89 | rwn | 2 |
| 90 | shu-mu | 2 |
| 91 | structural-change | 2 |
| 92 | threonines | 2 |
| 93 | treatmentthe | 2 |
| 94 | ultegra | 2 |
| 95 | β₀ | 2 |
| 96 | +13.54 | 1 |
| 97 | +1·33 | 1 |
| 98 | -26·5 | 1 |
| 99 | /adc | 1 |
| 100 | 0.00-0.47 | 1 |
| 101 | 0.00116 | 1 |
| 102 | 0.00353 | 1 |
| 103 | 1.84mmse | 1 |
| 104 | 10-percentage | 1 |
| 105 | 10.7-19.3 | 1 |
| 106 | 10th-percentile | 1 |
| 107 | 17-ms | 1 |
| 108 | 17-percentage | 1 |
| 109 | 190,000-da | 1 |
| 110 | 2.876 | 1 |
| 111 | 20-voxel | 1 |
| 112 | 2005.the | 1 |
| 113 | 25-30-hour | 1 |
| 114 | 3·56 | 1 |
| 115 | 4.71+0.75 | 1 |
| 116 | 5.9+/-6.5 | 1 |
| 117 | 5th-min | 1 |
| 118 | 5y-expressing | 1 |
| 119 | 65-kilodalton | 1 |
| 120 | 7.5-percentage | 1 |
| 121 | accumulatory | 1 |
| 122 | acute-poisoning | 1 |
| 123 | ahshi | 1 |
| 124 | algorithm-determined | 1 |
| 125 | assay-defined | 1 |
| 126 | auc0-72h | 1 |
| 127 | aζ | 1 |
| 128 | b0,700 | 1 |
| 129 | bis/se | 1 |
| 130 | bubble-end | 1 |
| 131 | cabe | 1 |
| 132 | collimation/wide | 1 |
| 133 | common-feature | 1 |
| 134 | concentration-curve | 1 |
| 135 | ctc50 | 1 |
| 136 | cut-in | 1 |
| 137 | d15-like | 1 |
| 138 | decision-theoretical | 1 |
| 139 | difference=21.2 | 1 |
| 140 | difference=5 | 1 |
| 141 | difference=6.5 | 1 |
| 142 | dose-taking | 1 |
| 143 | dr/ | 1 |
| 144 | dual-acid | 1 |
| 145 | eflornithine-associated | 1 |
| 146 | expansivity | 1 |
| 147 | features-a | 1 |
| 148 | first-care | 1 |
| 149 | formula-derived | 1 |
| 150 | frax-based | 1 |
| 151 | g405-d | 1 |
| 152 | gilts/time | 1 |
| 153 | gray/year | 1 |
| 154 | heart-to | 1 |
| 155 | hgbaic | 1 |
| 156 | high-inoculum | 1 |
| 157 | higher-than-neutral | 1 |
| 158 | hue-angle | 1 |
| 159 | index/valvuloarterial | 1 |
| 160 | inflammability | 1 |
| 161 | isolectric | 1 |
| 162 | jiantong | 1 |
| 163 | lab-sic-prepared | 1 |
| 164 | load-at-fracture | 1 |
| 165 | low-circulating | 1 |
| 166 | low-inoculum | 1 |
| 167 | managementand | 1 |
| 168 | meaningful/practical | 1 |
| 169 | mechanical-detection | 1 |
| 170 | medium-rough | 1 |
| 171 | microci/g | 1 |
| 172 | microrough | 1 |
| 173 | middlemost | 1 |
| 174 | milliamperage-second | 1 |
| 175 | minimal-efficacy | 1 |
| 176 | molecular/systems | 1 |
| 177 | mp4/aug-cc-pvdz | 1 |
| 178 | mu/control | 1 |
| 179 | multi-time | 1 |
| 180 | muscosal | 1 |
| 181 | n=8/time | 1 |
| 182 | near-0 | 1 |
| 183 | non-annoying | 1 |
| 184 | of/altered | 1 |
| 185 | parasite-density | 1 |
| 186 | patients/dose | 1 |
| 187 | persulfate-to-fe | 1 |
| 188 | pinkish | 1 |
| 189 | population-policy | 1 |
| 190 | post‑mitochondrial | 1 |
| 191 | practices.by | 1 |
| 192 | pre-dredging | 1 |
| 193 | prerash-acclimatized | 1 |
| 194 | reported≥10 | 1 |
| 195 | ridian | 1 |
| 196 | rnam | 1 |
| 197 | roc-determined | 1 |
| 198 | rough-textured | 1 |
| 199 | screening-risk | 1 |
| 200 | shu-mu-he | 1 |
| 201 | similar-temperature | 1 |
| 202 | sites:6 | 1 |
| 203 | small-fiber-associated | 1 |
| 204 | species-wide | 1 |
| 205 | sub-mw | 1 |
| 206 | td10 | 1 |
| 207 | thermo-toxicity | 1 |
| 208 | treponemicidal | 1 |
| 209 | trial-entry | 1 |
| 210 | two-e | 1 |
| 211 | ult₅₀ | 1 |
| 212 | unpreloaded | 1 |
| 213 | value-baseline | 1 |
| 214 | vessel-plaque | 1 |
| 215 | vibrometer-detected | 1 |
| 216 | vitronectin-coated | 1 |
| 217 | who-established | 1 |
| 218 | years.avp | 1 |
| 219 | ~107 | 1 |
| 220 | β=1.94 | 1 |
| 221 | β=5.55 | 1 |
| 222 | β=5.81 | 1 |
| 223 | δdd | 1 |
| 224 | δecouli | 1 |
| 225 | ∼30,000 | 1 |
| 226 | ≥7.50 | 1 |
| 1 | 'threshold | 6 |
| 2 | +13.54 | 1 |
| 3 | +1·33 | 1 |
| 4 | -26·5 | 1 |
| 5 | /adc | 1 |
| 6 | 0.00-0.47 | 1 |
| 7 | 0.00116 | 1 |
| 8 | 0.00353 | 1 |
| 9 | 1.84mmse | 1 |
| 10 | 10-percentage | 1 |
| 11 | 10.7-19.3 | 1 |
| 12 | 10th-percentile | 1 |
| 13 | 17-ms | 1 |
| 14 | 17-percentage | 1 |
| 15 | 190,000-da | 1 |
| 16 | 2.876 | 1 |
| 17 | 20-voxel | 1 |
| 18 | 2005.the | 1 |
| 19 | 25-30-hour | 1 |
| 20 | 3·56 | 1 |
| 21 | 4.71+0.75 | 1 |
| 22 | 5.9+/-6.5 | 1 |
| 23 | 5th-min | 1 |
| 24 | 5y-expressing | 1 |
| 25 | 65-kilodalton | 1 |
| 26 | 7.5-percentage | 1 |
| 27 | 9th-grade | 4 |
| 28 | accumulatory | 1 |
| 29 | acute-poisoning | 1 |
| 30 | age-distribution | 3 |
| 31 | ahshi | 1 |
| 32 | algorithm-determined | 1 |
| 33 | ar-model | 2 |
| 34 | assay-defined | 1 |
| 35 | auc0-72h | 1 |
| 36 | aucplasma | 5 |
| 37 | aunp/gce | 4 |
| 38 | aζ | 1 |
| 39 | b0,700 | 1 |
| 40 | b3lyp/6-31g* | 10 |
| 41 | bis/se | 1 |
| 42 | blood-oxygen | 2 |
| 43 | break-even | 20 |
| 44 | bubble-end | 1 |
| 45 | cabe | 1 |
| 46 | caliche | 7 |
| 47 | carborhodation | 5 |
| 48 | cbfb-myh11 | 3 |
| 49 | cho/naa | 10 |
| 50 | cis-interaction | 3 |
| 51 | collimation/wide | 1 |
| 52 | comlex-usa | 11 |
| 53 | common-feature | 1 |
| 54 | concentration-curve | 1 |
| 55 | constant-murley-score | 2 |
| 56 | creatinine-clearance | 2 |
| 57 | ctc50 | 1 |
| 58 | curcumin-based | 3 |
| 59 | cut-in | 1 |
| 60 | cut-of | 2 |
| 61 | cut-off | 1,599 |
| 62 | cutoff | 1,505 |
| 63 | cutpoint | 50 |
| 64 | d-10 | 7 |
| 65 | d15-like | 1 |
| 66 | d58 | 2 |
| 67 | decision-theoretical | 1 |
| 68 | desmoglein-2 | 2 |
| 69 | dew | 12 |
| 70 | dft-computed | 2 |
| 71 | difference=21.2 | 1 |
| 72 | difference=5 | 1 |
| 73 | difference=6.5 | 1 |
| 74 | dose-taking | 1 |
| 75 | dr/ | 1 |
| 76 | druid | 2 |
| 77 | dual-acid | 1 |
| 78 | eflornithine-associated | 1 |
| 79 | elisa-igg | 2 |
| 80 | empiriocriticist | 2 |
| 81 | ep-determined | 2 |
| 82 | etsev | 2 |
| 83 | expansivity | 1 |
| 84 | ezscan | 11 |
| 85 | features-a | 1 |
| 86 | fermi | 113 |
| 87 | first-care | 1 |
| 88 | formula-derived | 1 |
| 89 | frax-based | 1 |
| 90 | fsvr | 7 |
| 91 | g405-d | 1 |
| 92 | gilts/time | 1 |
| 93 | gray/year | 1 |
| 94 | he-sea | 18 |
| 95 | heart-to | 1 |
| 96 | hgbaic | 1 |
| 97 | high-current | 7 |
| 98 | high-hb | 5 |
| 99 | high-inoculum | 1 |
| 100 | high-tli | 2 |
| 101 | higher-than-neutral | 1 |
| 102 | historical-control | 2 |
| 103 | hlb | 26 |
| 104 | horrat | 3 |
| 105 | hrr₆₀ | 8 |
| 106 | hue-angle | 1 |
| 107 | icru | 18 |
| 108 | index/valvuloarterial | 1 |
| 109 | inflammability | 1 |
| 110 | inflection | 81 |
| 111 | insulative | 7 |
| 112 | isoelectric | 138 |
| 113 | isolectric | 1 |
| 114 | jiantong | 1 |
| 115 | kid21 | 3 |
| 116 | knuckle | 7 |
| 117 | lab-sic-prepared | 1 |
| 118 | ldl-lipoprotein | 2 |
| 119 | load-at-fracture | 1 |
| 120 | low-circulating | 1 |
| 121 | low-hb | 2 |
| 122 | low-inoculum | 1 |
| 123 | lt₅₀ | 3 |
| 124 | lǜ | 2 |
| 125 | machine-milled | 2 |
| 126 | managementand | 1 |
| 127 | maxwellian | 7 |
| 128 | meaningful/practical | 1 |
| 129 | mechanical-detection | 1 |
| 130 | medium-rough | 1 |
| 131 | microci/g | 1 |
| 132 | microrough | 1 |
| 133 | middlemost | 1 |
| 134 | milliamperage-second | 1 |
| 135 | millipede | 2 |
| 136 | minimal-efficacy | 1 |
| 137 | molecular/systems | 1 |
| 138 | mp4/aug-cc-pvdz | 1 |
| 139 | mu/control | 1 |
| 140 | multi-time | 1 |
| 141 | muscosal | 1 |
| 142 | n=8/time | 1 |
| 143 | nadir | 468 |
| 144 | near-0 | 1 |
| 145 | neck-occiput | 4 |
| 146 | nfw | 3 |
| 147 | no-observed-adverse-effect | 11 |
| 148 | non-annoying | 1 |
| 149 | nonmeridian | 3 |
| 150 | nonwear | 7 |
| 151 | of/altered | 1 |
| 152 | oracfl | 2 |
| 153 | osteo-induction | 2 |
| 154 | parasite-density | 1 |
| 155 | patients/dose | 1 |
| 156 | percent-weight-loss | 2 |
| 157 | persulfate-to-fe | 1 |
| 158 | phbhhx-l | 4 |
| 159 | pinkish | 1 |
| 160 | pmadl-8 | 9 |
| 161 | population-policy | 1 |
| 162 | post‑mitochondrial | 1 |
| 163 | practices.by | 1 |
| 164 | pre-activation | 8 |
| 165 | pre-dredging | 1 |
| 166 | pre-fasting | 2 |
| 167 | pre-program | 6 |
| 168 | prerash-acclimatized | 1 |
| 169 | proof-of-efficacy | 2 |
| 170 | rcof | 12 |
| 171 | reculture | 2 |
| 172 | repeat-induced | 2 |
| 173 | reported≥10 | 1 |
| 174 | respiratory-compensation | 2 |
| 175 | ridian | 1 |
| 176 | rnam | 1 |
| 177 | roc-determined | 1 |
| 178 | romhilt-estes | 4 |
| 179 | rothera | 2 |
| 180 | rough-textured | 1 |
| 181 | rwn | 2 |
| 182 | screening-risk | 1 |
| 183 | shu-mu | 2 |
| 184 | shu-mu-he | 1 |
| 185 | similar-temperature | 1 |
| 186 | sites:6 | 1 |
| 187 | small-fiber-associated | 1 |
| 188 | species-wide | 1 |
| 189 | structural-change | 2 |
| 190 | sub-mw | 1 |
| 191 | supercooling | 15 |
| 192 | t1rho | 9 |
| 193 | td10 | 1 |
| 194 | thermo-toxicity | 1 |
| 195 | threonines | 2 |
| 196 | time-integral | 5 |
| 197 | tonset | 8 |
| 198 | top | 1,555 |
| 199 | treatmentthe | 2 |
| 200 | treponemicidal | 1 |
| 201 | trial-entry | 1 |
| 202 | tricritical | 5 |
| 203 | tvlat | 4 |
| 204 | twilight | 3 |
| 205 | two-e | 1 |
| 206 | ultegra | 2 |
| 207 | ult₅₀ | 1 |
| 208 | unpreloaded | 1 |
| 209 | value-baseline | 1 |
| 210 | vessel-plaque | 1 |
| 211 | vibrometer-detected | 1 |
| 212 | vitronectin-coated | 1 |
| 213 | who-established | 1 |
| 214 | who-teq | 6 |
| 215 | willingness-to-pay | 146 |
| 216 | wuxin | 3 |
| 217 | years.avp | 1 |
| 218 | ~107 | 1 |
| 219 | β=1.94 | 1 |
| 220 | β=5.55 | 1 |
| 221 | β=5.81 | 1 |
| 222 | β₀ | 2 |
| 223 | δdd | 1 |
| 224 | δecouli | 1 |
| 225 | ∼30,000 | 1 |
| 226 | ≥7.50 | 1 |
| 1 | b3lyp/6-31g* | 10 |
| 2 | dr/ | 1 |
| 3 | near-0 | 1 |
| 4 | ∼30,000 | 1 |
| 5 | b0,700 | 1 |
| 6 | d-10 | 7 |
| 7 | td10 | 1 |
| 8 | reported≥10 | 1 |
| 9 | ≥7.50 | 1 |
| 10 | ctc50 | 1 |
| 11 | cbfb-myh11 | 3 |
| 12 | kid21 | 3 |
| 13 | β=5.81 | 1 |
| 14 | desmoglein-2 | 2 |
| 15 | difference=21.2 | 1 |
| 16 | 10.7-19.3 | 1 |
| 17 | +1·33 | 1 |
| 18 | 0.00353 | 1 |
| 19 | +13.54 | 1 |
| 20 | β=1.94 | 1 |
| 21 | 5.9+/-6.5 | 1 |
| 22 | difference=6.5 | 1 |
| 23 | β=5.55 | 1 |
| 24 | 4.71+0.75 | 1 |
| 25 | difference=5 | 1 |
| 26 | -26·5 | 1 |
| 27 | 0.00116 | 1 |
| 28 | 3·56 | 1 |
| 29 | 2.876 | 1 |
| 30 | sites:6 | 1 |
| 31 | ~107 | 1 |
| 32 | 0.00-0.47 | 1 |
| 33 | pmadl-8 | 9 |
| 34 | d58 | 2 |
| 35 | features-a | 1 |
| 36 | cho/naa | 10 |
| 37 | 190,000-da | 1 |
| 38 | he-sea | 18 |
| 39 | aucplasma | 5 |
| 40 | rothera | 2 |
| 41 | ultegra | 2 |
| 42 | comlex-usa | 11 |
| 43 | high-hb | 5 |
| 44 | low-hb | 2 |
| 45 | hlb | 26 |
| 46 | /adc | 1 |
| 47 | hgbaic | 1 |
| 48 | isoelectric | 138 |
| 49 | isolectric | 1 |
| 50 | g405-d | 1 |
| 51 | δdd | 1 |
| 52 | repeat-induced | 2 |
| 53 | unpreloaded | 1 |
| 54 | who-established | 1 |
| 55 | machine-milled | 2 |
| 56 | assay-defined | 1 |
| 57 | roc-determined | 1 |
| 58 | algorithm-determined | 1 |
| 59 | ep-determined | 2 |
| 60 | lab-sic-prepared | 1 |
| 61 | of/altered | 1 |
| 62 | rough-textured | 1 |
| 63 | curcumin-based | 3 |
| 64 | frax-based | 1 |
| 65 | eflornithine-associated | 1 |
| 66 | small-fiber-associated | 1 |
| 67 | vitronectin-coated | 1 |
| 68 | vibrometer-detected | 1 |
| 69 | dft-computed | 2 |
| 70 | formula-derived | 1 |
| 71 | prerash-acclimatized | 1 |
| 72 | dual-acid | 1 |
| 73 | druid | 2 |
| 74 | 'threshold | 6 |
| 75 | managementand | 1 |
| 76 | bubble-end | 1 |
| 77 | milliamperage-second | 1 |
| 78 | two-e | 1 |
| 79 | cabe | 1 |
| 80 | aunp/gce | 4 |
| 81 | creatinine-clearance | 2 |
| 82 | 9th-grade | 4 |
| 83 | millipede | 2 |
| 84 | species-wide | 1 |
| 85 | collimation/wide | 1 |
| 86 | persulfate-to-fe | 1 |
| 87 | 10-percentage | 1 |
| 88 | 7.5-percentage | 1 |
| 89 | 17-percentage | 1 |
| 90 | structural-change | 2 |
| 91 | shu-mu-he | 1 |
| 92 | caliche | 7 |
| 93 | 2005.the | 1 |
| 94 | treatmentthe | 2 |
| 95 | d15-like | 1 |
| 96 | hue-angle | 1 |
| 97 | 10th-percentile | 1 |
| 98 | knuckle | 7 |
| 99 | multi-time | 1 |
| 100 | n=8/time | 1 |
| 101 | gilts/time | 1 |
| 102 | value-baseline | 1 |
| 103 | first-care | 1 |
| 104 | constant-murley-score | 2 |
| 105 | common-feature | 1 |
| 106 | similar-temperature | 1 |
| 107 | load-at-fracture | 1 |
| 108 | reculture | 2 |
| 109 | bis/se | 1 |
| 110 | 1.84mmse | 1 |
| 111 | patients/dose | 1 |
| 112 | vessel-plaque | 1 |
| 113 | insulative | 7 |
| 114 | concentration-curve | 1 |
| 115 | cut-off | 1,599 |
| 116 | cutoff | 1,505 |
| 117 | cut-of | 2 |
| 118 | rcof | 12 |
| 119 | microci/g | 1 |
| 120 | elisa-igg | 2 |
| 121 | pre-dredging | 1 |
| 122 | dose-taking | 1 |
| 123 | supercooling | 15 |
| 124 | acute-poisoning | 1 |
| 125 | 5y-expressing | 1 |
| 126 | low-circulating | 1 |
| 127 | pre-fasting | 2 |
| 128 | non-annoying | 1 |
| 129 | jiantong | 1 |
| 130 | auc0-72h | 1 |
| 131 | medium-rough | 1 |
| 132 | microrough | 1 |
| 133 | pinkish | 1 |
| 134 | ahshi | 1 |
| 135 | high-tli | 2 |
| 136 | δecouli | 1 |
| 137 | fermi | 113 |
| 138 | screening-risk | 1 |
| 139 | phbhhx-l | 4 |
| 140 | meaningful/practical | 1 |
| 141 | decision-theoretical | 1 |
| 142 | tricritical | 5 |
| 143 | treponemicidal | 1 |
| 144 | post‑mitochondrial | 1 |
| 145 | index/valvuloarterial | 1 |
| 146 | time-integral | 5 |
| 147 | higher-than-neutral | 1 |
| 148 | muscosal | 1 |
| 149 | ar-model | 2 |
| 150 | 20-voxel | 1 |
| 151 | oracfl | 2 |
| 152 | historical-control | 2 |
| 153 | mu/control | 1 |
| 154 | rnam | 1 |
| 155 | pre-program | 6 |
| 156 | high-inoculum | 1 |
| 157 | low-inoculum | 1 |
| 158 | ezscan | 11 |
| 159 | ridian | 1 |
| 160 | nonmeridian | 3 |
| 161 | maxwellian | 7 |
| 162 | blood-oxygen | 2 |
| 163 | break-even | 20 |
| 164 | cut-in | 1 |
| 165 | ldl-lipoprotein | 2 |
| 166 | 5th-min | 1 |
| 167 | wuxin | 3 |
| 168 | carborhodation | 5 |
| 169 | respiratory-compensation | 2 |
| 170 | pre-activation | 8 |
| 171 | cis-interaction | 3 |
| 172 | inflection | 81 |
| 173 | mechanical-detection | 1 |
| 174 | osteo-induction | 2 |
| 175 | age-distribution | 3 |
| 176 | 65-kilodalton | 1 |
| 177 | rwn | 2 |
| 178 | t1rho | 9 |
| 179 | heart-to | 1 |
| 180 | top | 1,555 |
| 181 | years.avp | 1 |
| 182 | who-teq | 6 |
| 183 | nonwear | 7 |
| 184 | gray/year | 1 |
| 185 | nadir | 468 |
| 186 | 25-30-hour | 1 |
| 187 | fsvr | 7 |
| 188 | threonines | 2 |
| 189 | romhilt-estes | 4 |
| 190 | 17-ms | 1 |
| 191 | molecular/systems | 1 |
| 192 | percent-weight-loss | 2 |
| 193 | tvlat | 4 |
| 194 | horrat | 3 |
| 195 | no-observed-adverse-effect | 11 |
| 196 | tonset | 8 |
| 197 | twilight | 3 |
| 198 | high-current | 7 |
| 199 | cutpoint | 50 |
| 200 | empiriocriticist | 2 |
| 201 | middlemost | 1 |
| 202 | neck-occiput | 4 |
| 203 | shu-mu | 2 |
| 204 | icru | 18 |
| 205 | etsev | 2 |
| 206 | dew | 12 |
| 207 | nfw | 3 |
| 208 | sub-mw | 1 |
| 209 | willingness-to-pay | 146 |
| 210 | practices.by | 1 |
| 211 | proof-of-efficacy | 2 |
| 212 | minimal-efficacy | 1 |
| 213 | population-policy | 1 |
| 214 | accumulatory | 1 |
| 215 | trial-entry | 1 |
| 216 | thermo-toxicity | 1 |
| 217 | inflammability | 1 |
| 218 | parasite-density | 1 |
| 219 | expansivity | 1 |
| 220 | mp4/aug-cc-pvdz | 1 |
| 221 | lt₅₀ | 3 |
| 222 | ult₅₀ | 1 |
| 223 | hrr₆₀ | 8 |
| 224 | β₀ | 2 |
| 225 | lǜ | 2 |
| 226 | aζ | 1 |